What is ibrutinib/ibrutinib?

Ibrutinib/Ibrutinib is a targeted therapy drug mainly used to treat certain types of hematological malignancies, such as B-cell lymphoma and chronic lymphocytic leukemia. The emergence of this drug has brought new hope and possibilities for the treatment of these diseases. Ibrutinib is indicated for the treatment of the following diseases:

1) Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in adult patients.

2) Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion in adult patients.

3) Wadenstrom's macroglobulinemia (WM) in adult patients.

4) Chronic graft-versus-host disease (cGVHD) in adult and pediatric patients 1 year and older after failure of one or more systemic therapies.

The mechanism of action of ibrutinib is very unique. It mainly works by inhibiting the activity ofBruton tyrosine kinase (BTK). BTK is a key enzyme in the B cell signaling pathway and is essential for the development, activation and survival of B cells. In diseases such as B-cell lymphoma and chronic lymphocytic leukemia, overactivity of BTK often leads to abnormal proliferation and spread of cancer cells. Ibrutinib can precisely bind to BTK, thereby blocking its signaling function, thereby inhibiting the growth and spread of cancer cells.

In addition, ibrutinib has a long half-life and good oral bioavailability, which allows patients to conveniently receive treatment and reduces hospitalization time and treatment costs. At the same time, the efficacy of ibrutinib is also very significant. Many patients have significantly improved their condition and even achieved long-term disease control after receiving treatment.